An Evidence Based Perspective on mRNA-SARS-CoV-2 Vaccine Development
Level 5 - mechanism / opinion, no new human data
Narrative review describing vaccine rationale and early trial status without primary human data or systematic synthesis.
OpenAlex W3020445608 · doi:10.12659/msm.924700
What was done
This is a narrative review describing the background and rationale for developing mRNA-based vaccines against SARS-CoV-2, focusing on the status of the lipid nanoparticle-encapsulated mRNA-1273 vaccine that entered Phase I clinical trials in March 2020.
What was found
The abstract provides no empirical data or quantitative findings. It discusses the initiation of Phase I trials for mRNA-1273 encoding the spike protein and notes the technological promise and logistical challenges requiring international collaboration.
Why it matters
The paper captures the early scientific rationale for mRNA platforms during the onset of the COVID-19 pandemic before Phase III efficacy trials were completed.
Limits
As an early narrative overview, it contains no primary data, statistical outcomes, or systematic review methodology.
Cited by
- context Moderna designed its COVID-19 mRNA vaccine within 24 hours of receiving the SARS-CoV-2 genetic sequence from Wuhan.